Keel Point’s Gilead Sciences GILD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$1.4M Buy
9,364
+2,296
+32% +$322K 0.06% 168
2026
Q2
$893K Buy
7,068
+464
+7% +$61.1K 0.05% 194
2026
Q1
$920K Sell
6,604
-868
-12% -$122K 0.06% 180
2025
Q4
$917K Buy
7,472
+1,449
+24% +$176K 0.06% 196
2025
Q3
$669K Sell
6,023
-175
-3% -$19.9K 0.04% 243
2025
Q2
$687K Buy
6,198
+259
+4% +$27.6K 0.05% 234
2025
Q1
$665K Buy
5,939
+1,578
+36% +$163K 0.05% 197
2024
Q4
$403K Sell
4,361
-404
-8% -$36.4K 0.03% 271
2024
Q3
$399K Buy
4,765
+1,368
+40% +$104K 0.03% 279
2024
Q2
$251K Buy
+3,397
New +$227K 0.02% 358
2020
Q2
– Sell
-3,338
Closed -$250K – 193
2020
Q1
$250K Buy
+3,338
New +$231K 0.03% 152
2017
Q3
– Sell
-3,123
Closed -$221K – 166
2017
Q2
$221K Buy
3,123
+12
+0.4% +$799 0.04% 145
2017
Q1
$211K Buy
3,111
+11
+0.4% +$773 0.04% 150
2016
Q4
$222K Buy
+3,100
New +$230K 0.05% 143

Other funds holding GILD

Keel Point's GILD Position: Q3 2026 in Review

Keel Point increased its Gilead Sciences (GILD) stake by 32% in Q3 2026, buying an estimated $322K and bringing the position to 9,364 shares worth $1.4M. The position accounts for 0.06% of the portfolio, ranked #168.

Keel Point first reported a position in GILD in Q4 2016 and has held it in 14 quarters since. 2,357 funds tracked by Wall St. Rank hold GILD as of Q3 2026.

  • Keel Point held 9,364 shares of Gilead Sciences worth $1.4M as of Q3 2026.
  • Keel Point bought 2,296 Gilead Sciences shares in Q3 2026, an estimated $322K.
  • Gilead Sciences made up 0.06% of Keel Point's portfolio in Q3 2026, its #168 holding.
  • Keel Point first reported a position in Gilead Sciences in Q4 2016 and has held it in 14 quarters since.
  • 2,357 funds tracked by Wall St. Rank held Gilead Sciences as of Q3 2026.

Based on Keel Point's 13F filing for Q3 2026, filed 16 Nov 2026.